Treatment

A new subgroup analysis from the Phase 3 PSMAddition trial  shows that adding the radioligand therapy Pluvicto to standard hormone-based treatment significantly improves outcomes for patients with metastatic hormone-sensitive prostate cancer. Researchers found that the treatment reduced the risk of disease progression on imaging by a similar amount across all patient groups, including those with […]

A new experimental drug, emiltatug ledadotin (Emi-Le), has shown encouraging results for patients with aggressive adenoid cystic carcinoma (ACC), a rare cancer that currently has no approved systemic treatments. Findings revealed that the B7-H4–targeted antibody-drug conjugate produced strong tumor responses in patients with advanced disease. Among 32 patients with particularly aggressive ACC, nearly 47% experienced

A combination of cadonilimab, a dual PD-1/CTLA-4 immunotherapy, and axitinib showed promising results as a first-line treatment for advanced non–clear cell renal cell carcinoma (nccRCC). In a phase 1b/2 trial involving 37 patients, the treatment achieved an objective response rate of 51.6%, while 96.8% of patients experienced disease control. The median progression-free survival was 14.2

A real-world study evaluated tarlatamab (Imdelltra) in 23 patients with extensive-stage small cell lung cancer (ES-SCLC), a group with higher disease burden than typical clinical trials. Many patients were older (median age 72), 61% had brain metastases, and 43% had received two or more prior treatments. Among 18 evaluable patients, the objective response rate was

Results from a phase 1/1b study suggest that combining pembrolizumab (Keytruda) with ficerafusp alfa (BCA101) may improve outcomes for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), particularly those with HPV-negative disease. Ficerafusp alfa is a novel antibody designed to block both EGFR and TGF-β, two pathways linked to treatment resistance.

New analyses from the phase 3 EPCORE FL-1 trial showed that adding epcoritamab (Epkinly) to lenalidomide and rituximab provides significantly better outcomes than lenalidomide and rituximab alone for patients with relapsed or refractory follicular lymphoma. Earlier results showed the triplet reduced the risk of disease progression or death by 79%, with an overall response rate

A phase 1b/2 study found that adding the IDH1 inhibitor ivosidenib to the standard combination of venetoclax and azacitidine produced deep and durable responses in patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) who were not candidates for intensive chemotherapy. The trial enrolled 40 patients with a median age of 72 years. Patients received

A large real-world study found that zanubrutinib (Brukinsa) was associated with better outcomes than acalabrutinib (Calquence) in patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers analyzed insurance claims data from nearly 16,800 patients, including 5,819 treated with zanubrutinib and 10,969 treated with acalabrutinib. Patient characteristics were similar between the

Researchers tested an existing cancer drug, panitumumab (Vectibix), in a rare and aggressive kidney cancer called SMARCB1-deficient renal medullary carcinoma. Because the drug is already approved for other cancers, they were able to quickly run a multi-region study in North America and Europe. In 26 heavily pretreated patients, the results were stronger than expected. About

During a virtual Case-Based Roundtable, Daniel Landau and community oncologists discussed frontline treatment options for a 65-year-old man with newly diagnosed poor-risk metastatic clear cell renal cell carcinoma (ccRCC) and extensive bone involvement. The panel agreed that the immediate priority in such patients is rapid tumor reduction to prevent complications such as spinal cord compression